No Data
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $172
BioNTech Analyst Ratings
Truist Financial Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $172
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
TheGerries : So when is our turn?
Den the Dragon : ,
Jaguar8 OP TheGerries : ???
103622690 DK : I admire you very much, and I want to know how you chose your choice from so many choices, and the upward trend was selected many times, and it exploded the next day... I really want to worship you as a master.
Jaguar8 OP 103622690 DK : If I have time and teach during weekends. It also takes experience to get the feel which stock are quite positive . There are misses too but often times they go up in the next days
View more comments...